Latest Onyx Pharmaceuticals Stories
Application Designed to Support Conversion of Accelerated to Full FDA Approval THOUSAND OAKS, Calif., March 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.
Study Met Primary Endpoint of Progression-Free Survival THOUSAND OAKS, Calif.
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Feb.
US Submission Designed to Support Conversion From Accelerated to Full FDA Approval and Expansion of Current Approved Indication THOUSAND OAKS, Calif.
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition THOUSAND OAKS, Calif.
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
BURLINGAME, Calif., Oct.
THOUSAND OAKS, Calif., Sept. 24, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc.
-Dr. Cagnoni Joins Non-Profit Organization Focused on Fostering Innovation and Collaboration to Strengthen the Bay Area BioEconomy- SAN FRANCISCO, Sept.